https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Treatable Traits in Airway Disease: From Theory to Practice https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50124 Wed 28 Feb 2024 16:17:49 AEDT ]]> Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52918 Wed 01 Nov 2023 09:31:20 AEDT ]]> Treatable Traits in Asthma: The Importance of Extrapulmonary Traits—GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55702 Tue 18 Jun 2024 12:40:28 AEST ]]> The overlap of lung tissue transcriptome of smoke exposed mice with human smoking and COPD https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33143 −26) and a 1.4 fold in the severe COPD -related genes (P = 2.3 × 10⁻¹²). There was no significant enrichment of the mice and human smoking-related genes in mild COPD signature. These data suggest that murine smoke models are strongly representative of molecular processes of human smoking but less of COPD.]]> Tue 03 Sep 2019 18:18:55 AEST ]]> Treatable Traits That Predict Health Status and Treatment Response in Airway Disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49876 3 mg/L), and depression. In both trials, TT treatment led to a large, significant improvement in HRQOL compared with usual care (Cohen's d = 1.19; P < .001). Receiving a statin for systemic inflammation and oral corticosteroid for eosinophilic airway inflammation was associated with the largest HRQOL improvements. Treatments for exercise intolerance, anxiety, and obesity were associated with smaller improvements in HRQOL. Conclusions: This study contributes to identifying clinically impactful TTs by showing that TTs across pulmonary, extrapulmonary, and behavioral domains were associated with HRQOL impairment and treatment response.]]> Thu 08 Jun 2023 15:21:50 AEST ]]> ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46840 Thu 01 Dec 2022 15:50:25 AEDT ]]> After asthma: redefining airways diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43034 Mon 12 Sep 2022 11:49:26 AEST ]]> Moving towards a Treatable Traits model of care for the management of obstructive airways diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48632 Fri 24 Mar 2023 10:57:01 AEDT ]]> From treatable traits to GETomics in airway disease: moving towards clinical practice https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54670 Fri 08 Mar 2024 11:32:27 AEDT ]]> Treatable traits: toward precision medicine of chronic airway diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24513 Fri 01 Apr 2022 09:29:32 AEDT ]]> Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36583 Fri 01 Apr 2022 09:23:30 AEDT ]]>